Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Algert Global LLC

Algert Global LLC grew its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 0.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 134,321 shares of the company’s stock after buying an additional 599 shares during the quarter. Algert Global LLC’s holdings in Castle Biosciences were worth $3,831,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its stake in shares of Castle Biosciences by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock worth $220,000 after acquiring an additional 675 shares in the last quarter. Assetmark Inc. boosted its position in Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after purchasing an additional 748 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Castle Biosciences by 10.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock valued at $215,000 after purchasing an additional 952 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Castle Biosciences by 6.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,034 shares of the company’s stock valued at $400,000 after buying an additional 1,131 shares in the last quarter. Finally, Quest Partners LLC raised its stake in shares of Castle Biosciences by 54.4% during the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after buying an additional 1,522 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. KeyCorp lifted their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Stephens reissued an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. Scotiabank raised their price target on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Robert W. Baird boosted their price objective on Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group raised their target price on Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Castle Biosciences has a consensus rating of “Buy” and a consensus price target of $37.88.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction on Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the sale, the insider now owns 94,622 shares in the company, valued at $2,718,490.06. The trade was a 1.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Frank Stokes sold 6,923 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $29.93, for a total value of $207,205.39. Following the completion of the transaction, the chief financial officer now directly owns 30,823 shares in the company, valued at approximately $922,532.39. This trade represents a 18.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,213 shares of company stock worth $752,673 in the last quarter. Company insiders own 7.20% of the company’s stock.

Castle Biosciences Trading Down 1.0 %

CSTL opened at $29.51 on Tuesday. The firm has a market capitalization of $826.58 million, a price-to-earnings ratio of 147.56 and a beta of 0.99. The company’s 50 day simple moving average is $30.96 and its two-hundred day simple moving average is $26.53. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. The firm had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same quarter last year, the business posted ($0.26) earnings per share. Analysts expect that Castle Biosciences, Inc. will post -0.08 EPS for the current fiscal year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.